Antisense Oligonucleotides Modulate PTP1B Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective options for treating metabolic disorders, particularly those associated with diabetes, as current treatments do not adequately address the negative regulation of insulin signaling by Protein Tyrosine Phosphatase 1B (PTP1B).
Innovation Solution
The development of methods and compositions that utilize antisense oligonucleotides, such as ISIS 404173, to specifically target and reduce the expression of PTP1B mRNA and protein, thereby modulating its activity and improving insulin sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional small molecule inhibitors are used to inhibit PTP1B, then competitive binding to the protein is required, but this approach has limited efficacy and safety profile
Solution Approach 1:
The patent replaces the mechanical/chemical binding mechanism of small molecule inhibitors with an antisense oligonucleotide mechanism that targets mRNA for degradation. This substitution eliminates the need for competitive binding to the protein, achieving superior efficacy and safety by directly reducing PTP1B expression rather than blocking its activity.
Solution Approach 2:
The antisense oligonucleotides perform preliminary action by degrading PTP1B mRNA before the protein can be synthesized. This preemptive approach to protein reduction provides more effective and sustained inhibition compared to traditional inhibitors that must continuously bind to the protein to maintain effect.
2Reliability
If antisense oligonucleotides are used to reduce PTP1B expression, then direct inhibition of mRNA translation is achieved, but specific targeting and delivery challenges arise
Solution Approach 1:
The patent applies local quality by designing antisense oligonucleotides with specific sequence complementarity to PTP1B mRNA, enabling precise targeting. The chemical modifications (such as phosphorothioate backbones and 2'-O-methoxyethyl sugar modifications) provide localized properties that enhance stability, specificity, and cellular uptake, achieving reliable inhibition without affecting other proteins.
3Adaptability or versatility
If PTP1B expression is reduced to improve insulin sensitivity, then metabolic disorders are ameliorated, but off-target effects and safety concerns may arise
Solution Approach 1:
The patent substitutes protein-targeting mechanisms with mRNA degradation mechanisms, achieving superior specificity. By targeting the mRNA molecule rather than the protein, the antisense oligonucleotides eliminate off-target binding issues inherent in small molecule inhibitors, while still achieving the desired therapeutic effect of improved insulin sensitivity and metabolic health.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods effectively decrease PTP1B protein expression, leading to improved insulin sensitivity, reduced glucose levels, and amelioration of metabolic disorders like diabetes and obesity, as demonstrated by significant reductions in PTP1B mRNA levels and improved tolerability in preclinical and tolerability studies.
Implementation Method 1
Antisense inhibition of PTP1B provides a unique advantage over traditional small molecule inhibitors in that antisense inhibitors do not rely on competitive binding of the compound to the protein and inhibit activity directly by reducing the expression of PTP1B.
Data Source
AI summary
Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.